# Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

> **NCT03359018** · PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 43 (actual)

## Conditions studied

- Progression-free Survival
- Overall Survival
- Clinical Benefit Rate
- Toxicity

## Interventions

- **DRUG:** Apatinib
- **DRUG:** SHR-1210

## Key facts

- **NCT ID:** NCT03359018
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2019-10-22
- **Final completion:** 2020-01-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359018, "Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03359018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*